-
Uncategorized2 weeks ago
Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division
Fortrea has agreed to acquire the early-phase services division of fellow CRO Worldwide Clinical Trials for $45 million.
-
Uncategorized2 weeks agoPartners explore T cell engaging approaches for solid tumours
Evotec and Plectonic Biotech have announced a research collaboration to explore a novel immunotherapy approach for solid tumours. The collaboration aims to address key challenges that...
-
Uncategorized2 weeks ago
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
CSL Vifor holds the marketing authorization for Tavneos in the U.K., where the drug is marketed as Avacopan Vifor. It continues to be sold on the...
-
Uncategorized2 weeks ago
Biopharma reverse mergers rise 1,600% in Q3 to rival IPOs
Almost as many biotechs have opted for a reverse merger to reach the public markets as those executing more traditional initial public offerings this year.
-
Uncategorized2 weeks ago
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
-
Uncategorized2 weeks ago
The physicochemical design, structure and permeability of the JCVI-syn3A minimal cell membrane
Post Content
-
Uncategorized2 weeks ago
Single-Cell Striatum Atlas Reveals Neurological Disorder Vulnerabilities
The striatum, a brain region involved in movement, decision-making, habit formation, and reward processing, is also implicated in some of the most difficult-to-treat neurological and psychiatric...
Ensuring safety and accountability in China’s biomedical translation system
Blood centers can help biopharma scale cell and gene therapies
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
